John Callison, MD
Pulmonary Disease · Knoxville, TNNPI 1528115334
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Intuitive Surgical at 45.1% of the total. Reporting peaked in 2022 at $4,040 and has fallen 82.9% since, to $693 in 2025.
Across 246 payments — averaging $31.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- GSK$727
- Actelion Pharmaceuticals US, Inc.$456
- Merck$353
- United Therapeutics Corporation$339
- AstraZeneca$339
- plus $2K from 37 others
Across 22 payments — averaging $14,398 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$317K
What the payments were for
- Travel & lodging$1852%
- Food & beverage$4,25655%
- Education$3,26342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,250
- Da Vinci Surgical System$179
How this compares
$7,704 in reported general payments places this provider in the 65th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 105 | $2,732,709 |
| ZenpepLipase/Protease/Amylase | 19 | $226,391 |
| CreonLipase/Protease/Amylase | 33 | $193,114 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,742 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $9,830 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,312 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,525 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,833 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,265 |
| Ventolin HfaAlbuterol Sulfate | 12 | $931 |
| Azithromycin | 29 | $697 |
| Famotidine | 26 | $506 |
| Azelastine Hcl | 16 | $424 |
| Fluticasone Propionate | 18 | $290 |
| Mirtazapine | 25 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $41 | $2,732,709105 claims |
| Aimmune Therapeutics, Inc.Zenpep | $29 | $226,39119 claims |
| AbbVieCreon | $334 | $193,11433 claims |
| GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta | $727 | $30,88465 claims |
| AstraZenecaSymbicort | $339 | $4,52518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Knoxville
- John SwisherKnoxville$234K
- John PrinceKnoxville$117K
- Rajiv DhandKnoxville$96K
- Varun ShahKnoxville$64K
- Benjamin BevillKnoxville$31K
- Shannon ByrdKnoxville$23K
- James PharaohKnoxville$20K
- Isaac BineyKnoxville$16K
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.